

August 9, 2023

The Manager- Listing

BSE Limited

Corporate Relationship Dept., 5th Floor, New Trading Ring
Rotunda Building, P J Towers, Dalal Street, Fort,
Mumbai - 400001

The Manager- Listing

National Stock Exchange of India Limited

Exchange Plaza, 5th Floor, Plot No. C/1, G Block
Bandra –Kurla Complex, Bandra (E),
Mumbai - 400051

Dear Sir(s),

Subject: Launch of Selumetinib 10 mg and 25 mg capsule (Koselugo)

We refer to our earlier communication dated September 26, 2021 intimating the receipt of Import and Market Permission in Form CT-20 from the Drugs Controller General of India for Selumetinib 10 mg and 25 mg capsule (Koselugo).

With regard to the same, we now wish to further update that AstraZeneca Pharma India Limited has launched Koselugo in India.

Selumetinib (Koselugo) is indicated for treatment of Pediatric patients 3 years of age and older with neurofibromatosis type 1 (NF1) and who have symptomatic, inoperable plexiform neurofibromas (PN).

We request you to kindly take the above on records.

Thanking You,

For **AstraZeneca Pharma India Limited**

Manasa. R
Company Secretary